Elsevier

Mayo Clinic Proceedings

Volume 84, Issue 9, September 2009, Pages 771-775
Mayo Clinic Proceedings

EDITORIAL
Bidirectional Conflicts of Interest Involving Industry and Medical Journals: Who Will Champion Integrity?

https://doi.org/10.4065/84.9.771Get rights and content

REFERENCES (85)

  • C De Angelis et al.

    Clinical trial registration: a statement from the International Committee of Medical Journal Editors [editorial]

    Lancet

    (2004)
  • CD De Angelis et al.

    Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors

    Lancet

    (2005)
  • C Laine et al.

    Clinical trial registration: looking back and moving ahead [editorial]

    Lancet

    (2007)
  • Institute of Medicine of the National Academies Web site

    Conflict of interest in medical research, education and practice. Released April 28, 2009

  • E Wager et al.

    Good publication practice for pharmaceutical companies

    Curr Med Res Opin

    (2003)
  • E Wager

    “Good publication practice for pharmaceutical companies”: where are we now?

    MedGenMed

    (2005)
  • KA Katz

    Time to nip “seeding trials” in the bud

    Arch Dermatol

    (2008)
  • S Sismondo

    Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry?

    PLoS Med

    (2007)
  • B Moffatt et al.

    Ghost marketing: pharmaceutical companies and ghostwritten journal articles

    Perspect Biol Med

    (2007)
  • TP Stossel

    Regulating academic industry research relationships-solving problems or stifling progress?

    N Engl J Med

    (2005)
  • JM Drazen et al.

    Financial associations of authors [editorial]

    N Engl J Med

    (2002)
  • KJ Rothman

    Conflict of interest: the new McCarthyism in science

    JAMA

    (1993)
  • EC Kendall
  • C Marwick

    Pharmacology researchers receive 1988 Nobel Prize

    JAMA

    (1988)
  • JL Marx

    The 1988 Nobel Prize for Physiology or Medicine

    Science

    (1988)
  • BA Chabner

    In celebration of a Nobel prize [editorial]

    J Natl Cancer Inst

    (1988)
  • C Bombardier et al.

    Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis

    N Engl J Med

    (2000)
  • D Armstrong

    The New England Journal missed Vioxx warning signs

  • GD Curfman et al.

    Expression of concern: Bombardier et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” N Engl J Med 2000;343:1520-8 [editorial]

    N Engl J Med

    (2005)
  • International Committee of Medical Journal Editors

    Sponsorship, authorship, and accountability. ICMJE Web site

  • International Committee of Medical Journal Editors

    Clinical trial registration. A statement from the International Committee of Medical Journal Editors. ICMJE Web site

  • International Committee of Medical Journal Editors

    ICMJE Web site. Is this clinical trial fully registered?: A statement from the International Committee of Medical Journal Editors

  • International Committee of Medical Journal Editors

    ICMJE Web site. Clinical trial registration. Looking back and moving ahead

  • F Davidoff et al.

    Sponsorship, authorship and accountability [editorial]

    JAMA

    (2001)
  • F Davidoff et al.

    Sponsorship, authorship and accountability [editorial]

    N Engl J Med

    (2001)
  • F Davidoff et al.

    Sponsorship, authorship and accountability [editorial]

    Ann Intern Med

    (2001)
  • F Davidoff et al.

    Sponsorship, authorship and accountability [editorial]

    CMAJ

    (2001)
  • F Davidoff et al.

    Sponsorship, authorship and accountability [editorial]

    Obstet Gynecol

    (2001)
  • F Davidoff et al.

    International Committee of Medical Journal Editors. Sponsorship, authorship and accountability [editorial]

    Med J Aust

    (2001)
  • F Davidoff et al.

    Sponsorship, authorship and accountability [editorial]

    Ugeskr Laeger

    (2001)
  • F Davidoff et al.

    Sponsorship, authorship and accountability [editorial]

    Arch Otolaryngol Head Neck Surg

    (2001)
  • F Davidoff et al.

    Sponsorship, authorship and accountability [in Norwegian] [editorial]

    Tidsskr Nor Laegeforen

    (2001)
  • Cited by (43)

    • Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: A joint journal and pharmaceutical industry perspective

      2012, Mayo Clinic Proceedings
      Citation Excerpt :

      These debates notwithstanding, however, editors and sponsors should support the use of the updated ICMJE Conflict of Interest Reporting Form19 and continue dialogue regarding its improvement. Furthermore, the same conflict of interest reporting standards should be applied uniformly to all authors, regardless of the source of research funding.20 To further enhance disclosure transparency and reduce the administrative burden on authors, all parties should also explore the feasibility of developing a centralized, publicly accessible disclosure database.21

    • Conflict of interest policies and disclosure requirements among European Society of Cardiology National Cardiovascular Journals

      2012, Revista Portuguesa de Cardiologia
      Citation Excerpt :

      Subtle biases in design and interpretation may arise when a sponsor stands to gain from the report.17 Pharmaceutical and technological companies are responsible for most important advancements in medical knowledge.17–24 Patients, doctors, and society as a whole benefit from this unique effort and should be grateful for the research commitment by the industry.

    • COX-2 inhibition: What we learned-A controversial update on safety data

      2013, Pain Medicine (United States)
      Citation Excerpt :

      In September 2009, Mayo Clinic Proceedings published both an article and an editorial on the financial and intangible incentives journals have to demonstrate bias against pharmaceutical industry research. This in turn generated a massive reader response, reflecting the enormity of this previously unrecognized issue [1–3]. The first step in reviewing c2sNSAID safety data would be defining what comprises a c2sNSAID.

    View all citing articles on Scopus

    Dr Lanier was a laboratory-based researcher at Mayo Clinic from 1983-2006 but currently focuses on clinical research. His research has been funded by multiple governmental, foundation, professional-association, and industry sources. Dr Lanier has not sought nor received industry funding for his research since becoming Editor-in-Chief of Mayo Clinic Proceedings in January 1999.

    View full text